Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Bluebird bio Inc is a biotechnology business based in the US. Bluebird bio shares (BLUE) are listed on the NASDAQ and all prices are listed in US Dollars. Bluebird bio employs 518 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $4.28 |
|---|---|
| 52-week range | $2.87 - $20.55 |
| 50-day moving average | $3.68 |
| 200-day moving average | $7.70 |
| Wall St. target price | $7.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-10.43 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.28 from 2022-07-01
| 1 week (2022-06-24) | -2.73% |
|---|---|
| 1 month (2022-06-01) | 44.11% |
| 3 months (2022-03-31) | -11.75% |
| 6 months (2021-12-31) | -57.16% |
| 1 year (2021-07-02) | -86.36% |
|---|---|
| 2 years (2020-07-02) | -92.81% |
| 3 years (2019-07-02) | 127.8 |
| 5 years (2017-06-30) | 104.9979 |
Valuing Bluebird bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bluebird bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bluebird bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bluebird bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $4.7 million |
|---|---|
| Gross profit TTM | $-351,136,000 |
| Return on assets TTM | -31.44% |
| Return on equity TTM | -76.97% |
| Profit margin | 0% |
| Book value | $3.69 |
| Market capitalisation | $305.8 million |
TTM: trailing 12 months
We're not expecting Bluebird bio to pay a dividend over the next 12 months.
Bluebird bio's shares were split on a 1544:1000 basis on 4 November 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1544 shares. This wouldn't directly have changed the overall worth of your Bluebird bio shares – just the quantity. However, indirectly, the new 35.2% lower share price could have impacted the market appetite for Bluebird bio shares which in turn could have impacted Bluebird bio's share price.
Over the last 12 months, Bluebird bio's shares have ranged in value from as little as $2.87 up to $20.5533. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bluebird bio's is 1.6887. This would suggest that Bluebird bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc. , and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
